Cortechs.ai | Restriction Spectrum Imaging (RSI) improves cancer detection
Cortechs.ai | Restriction Spectrum Imaging (RSI) improves cancer detection
RSNA 2025
Contact

Restriction Spectrum Imaging (RSI) improves cancer detection

  • Category: Published research
  • Product: OnQ Prostate
  • Disease: Prostate cancer

Compares the diagnostic performance of restriction spectrum imaging (RSI), with that of conventional multi-parametric (MP) magnetic resonance imaging (MRI) for prostate cancer (PCa) detection in a blinded reader-based format. 2016.

Read Here >> 

  • Topic: Published research

More Resources

Cortechs Cares: Community Impact and Volunteer Efforts in 2025
  • 2 mins

03/13/2026

Cortechs Cares: Community Impact and Volunteer Efforts in 2025

Cortechs Cares highlights how our team gave back in 2025 through community volunteer efforts, including an Alzheimer’s Walk and holiday toy drive.

Cortechs.ai | Restriction Spectrum Imaging (RSI) improves cancer detection
  • 2 mins

03/11/2026

OnQ™ Prostate: Bringing Quantitative MRI to Prostate Imaging

Advancing prostate MRI with quantitative diffusion biomarkers. OnQ™ Prostate brings objective RSI-based insights to support data-driven cancer evaluation.

Cortechs.ai | Restriction Spectrum Imaging (RSI) improves cancer detection
  • 2 mins

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

, ,

Cortechs.ai | Restriction Spectrum Imaging (RSI) improves cancer detection
  • 2 mins

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.

, ,

Cortechs.ai | Restriction Spectrum Imaging (RSI) improves cancer detection
  • < 1 mins

02/24/2026

Financial Conflict Of Interest Policy Applicable To NIH Awards

Cortechs.ai | Restriction Spectrum Imaging (RSI) improves cancer detection
  • 2 mins

02/20/2026

NeuroQuant® PET: FDA 510(k)-Pending Advancement in Molecular Dementia Imaging

FDA 510(k)-Pending NeuroQuant® PET delivers automated, standardized quantification for amyloid, tau, and FDG imaging in dementia care.

,

View our insights
Cortechs.ai | Restriction Spectrum Imaging (RSI) improves cancer detection
Cortechs.ai | Restriction Spectrum Imaging (RSI) improves cancer detection

Empowering precision

and clarity in patient care

727 Madison Ave, Suite 29, Covington, Kentucky 41011

Headquarters:

5060 Shoreham Place,
Ste 240, San Diego, CA 92122

Cortechs.ai | Restriction Spectrum Imaging (RSI) improves cancer detection
Cortechs.ai | Restriction Spectrum Imaging (RSI) improves cancer detection
  • Solutions
  • © Cortechs.ai 2024
Scroll to Top